PMID- 25179850
OWN - NLM
STAT- MEDLINE
DCOM- 20160516
LR  - 20171116
IS  - 1499-2752 (Electronic)
IS  - 0315-162X (Linking)
VI  - 41
IP  - 10
DP  - 2014 Oct
TI  - Disease activity improvement in rheumatoid arthritis treated with tumor necrosis 
      factor-alpha inhibitors correlates with increased soluble Fas levels.
PG  - 1961-5
LID - 10.3899/jrheum.131544 [doi]
AB  - OBJECTIVE: Rheumatoid arthritis (RA) is characterized by chronic synovial 
      inflammation and hyperplasia. Tumor necrosis factor-alpha (TNF-alpha) plays a pivotal 
      role in RA by interfering with the Fas-Fas ligand (FasL) proapoptotic pathway. We 
      investigated the circulating levels of soluble Fas (sFas) and soluble FasL 
      (sFasL), and their possible correlation with disease activity and improvement 
      after anti-TNF-alpha treatment in RA. METHODS: Serum levels of sFas and sFasL were 
      measured by quantitative ELISA in 52 patients with RA before and after 3 months 
      of anti-TNF-alpha treatment (adalimumab, n = 32; infliximab, n = 20). Disease 
      activity measures [Disease Activity Score at 28 joints-erythrocyte sedimentation 
      rate (DAS28-ESR), C-reactive protein (CRP)] were recorded before and after 
      treatment. Forty age-matched and sex-matched healthy subjects served as controls. 
      RESULTS: No significant differences in serum sFas levels were detected between 
      anti-TNF-alpha-naive patients with RA and controls. After anti-TNF-alpha treatment, serum 
      sFas levels significantly increased in patients with RA compared to both 
      anti-TNF-alpha-naive patients and controls. Increased sFas levels inversely 
      correlated with disease activity variables (DAS28-ESR: r = -0.739, CRP: r = 
      -0.636, both p < 0.001). No significant differences in sFasL levels were detected 
      in patients with RA before and after anti-TNF-alpha treatment. CONCLUSION: In RA, an 
      increase in sFas levels closely correlates with improvement in disease activity 
      induced by TNF-alpha inhibitors, suggesting their ability to modulate Fas-mediated 
      synoviocyte apoptosis.
FAU - Romano, Eloisa
AU  - Romano E
AD  - From the Department of Experimental and Clinical Medicine, Section of Internal 
      Medicine; Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; 
      DENOthe Centre; Department of Experimental and Clinical Medicine, Section of 
      Anatomy and Histology, University of Florence, Florence, Italy.E. Romano, PhD; R. 
      Terenzi, MD; F. Peruzzi, MD; G. Fiori, MD; F. Nacci, MD; S. Bellando-Randone, MD, 
      PhD; M. Matucci-Cerinic, MD, PhD; S. Guiducci, MD, PhD, Department of 
      Experimental and Clinical Medicine, Section of Internal Medicine, Division of 
      Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; M. 
      Manetti, PhD; Department of Experimental and Clinical Medicine, Section of 
      Anatomy and Histology, University of Florence. eloisaromano@libero.it.
FAU - Terenzi, Riccardo
AU  - Terenzi R
AD  - From the Department of Experimental and Clinical Medicine, Section of Internal 
      Medicine; Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; 
      DENOthe Centre; Department of Experimental and Clinical Medicine, Section of 
      Anatomy and Histology, University of Florence, Florence, Italy.E. Romano, PhD; R. 
      Terenzi, MD; F. Peruzzi, MD; G. Fiori, MD; F. Nacci, MD; S. Bellando-Randone, MD, 
      PhD; M. Matucci-Cerinic, MD, PhD; S. Guiducci, MD, PhD, Department of 
      Experimental and Clinical Medicine, Section of Internal Medicine, Division of 
      Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; M. 
      Manetti, PhD; Department of Experimental and Clinical Medicine, Section of 
      Anatomy and Histology, University of Florence.
FAU - Manetti, Mirko
AU  - Manetti M
AD  - From the Department of Experimental and Clinical Medicine, Section of Internal 
      Medicine; Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; 
      DENOthe Centre; Department of Experimental and Clinical Medicine, Section of 
      Anatomy and Histology, University of Florence, Florence, Italy.E. Romano, PhD; R. 
      Terenzi, MD; F. Peruzzi, MD; G. Fiori, MD; F. Nacci, MD; S. Bellando-Randone, MD, 
      PhD; M. Matucci-Cerinic, MD, PhD; S. Guiducci, MD, PhD, Department of 
      Experimental and Clinical Medicine, Section of Internal Medicine, Division of 
      Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; M. 
      Manetti, PhD; Department of Experimental and Clinical Medicine, Section of 
      Anatomy and Histology, University of Florence.
FAU - Peruzzi, Francesca
AU  - Peruzzi F
AD  - From the Department of Experimental and Clinical Medicine, Section of Internal 
      Medicine; Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; 
      DENOthe Centre; Department of Experimental and Clinical Medicine, Section of 
      Anatomy and Histology, University of Florence, Florence, Italy.E. Romano, PhD; R. 
      Terenzi, MD; F. Peruzzi, MD; G. Fiori, MD; F. Nacci, MD; S. Bellando-Randone, MD, 
      PhD; M. Matucci-Cerinic, MD, PhD; S. Guiducci, MD, PhD, Department of 
      Experimental and Clinical Medicine, Section of Internal Medicine, Division of 
      Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; M. 
      Manetti, PhD; Department of Experimental and Clinical Medicine, Section of 
      Anatomy and Histology, University of Florence.
FAU - Fiori, Ginevra
AU  - Fiori G
AD  - From the Department of Experimental and Clinical Medicine, Section of Internal 
      Medicine; Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; 
      DENOthe Centre; Department of Experimental and Clinical Medicine, Section of 
      Anatomy and Histology, University of Florence, Florence, Italy.E. Romano, PhD; R. 
      Terenzi, MD; F. Peruzzi, MD; G. Fiori, MD; F. Nacci, MD; S. Bellando-Randone, MD, 
      PhD; M. Matucci-Cerinic, MD, PhD; S. Guiducci, MD, PhD, Department of 
      Experimental and Clinical Medicine, Section of Internal Medicine, Division of 
      Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; M. 
      Manetti, PhD; Department of Experimental and Clinical Medicine, Section of 
      Anatomy and Histology, University of Florence.
FAU - Nacci, Francesca
AU  - Nacci F
AD  - From the Department of Experimental and Clinical Medicine, Section of Internal 
      Medicine; Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; 
      DENOthe Centre; Department of Experimental and Clinical Medicine, Section of 
      Anatomy and Histology, University of Florence, Florence, Italy.E. Romano, PhD; R. 
      Terenzi, MD; F. Peruzzi, MD; G. Fiori, MD; F. Nacci, MD; S. Bellando-Randone, MD, 
      PhD; M. Matucci-Cerinic, MD, PhD; S. Guiducci, MD, PhD, Department of 
      Experimental and Clinical Medicine, Section of Internal Medicine, Division of 
      Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; M. 
      Manetti, PhD; Department of Experimental and Clinical Medicine, Section of 
      Anatomy and Histology, University of Florence.
FAU - Bellando-Randone, Silvia
AU  - Bellando-Randone S
AD  - From the Department of Experimental and Clinical Medicine, Section of Internal 
      Medicine; Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; 
      DENOthe Centre; Department of Experimental and Clinical Medicine, Section of 
      Anatomy and Histology, University of Florence, Florence, Italy.E. Romano, PhD; R. 
      Terenzi, MD; F. Peruzzi, MD; G. Fiori, MD; F. Nacci, MD; S. Bellando-Randone, MD, 
      PhD; M. Matucci-Cerinic, MD, PhD; S. Guiducci, MD, PhD, Department of 
      Experimental and Clinical Medicine, Section of Internal Medicine, Division of 
      Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; M. 
      Manetti, PhD; Department of Experimental and Clinical Medicine, Section of 
      Anatomy and Histology, University of Florence.
FAU - Matucci-Cerinic, Marco
AU  - Matucci-Cerinic M
AD  - From the Department of Experimental and Clinical Medicine, Section of Internal 
      Medicine; Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; 
      DENOthe Centre; Department of Experimental and Clinical Medicine, Section of 
      Anatomy and Histology, University of Florence, Florence, Italy.E. Romano, PhD; R. 
      Terenzi, MD; F. Peruzzi, MD; G. Fiori, MD; F. Nacci, MD; S. Bellando-Randone, MD, 
      PhD; M. Matucci-Cerinic, MD, PhD; S. Guiducci, MD, PhD, Department of 
      Experimental and Clinical Medicine, Section of Internal Medicine, Division of 
      Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; M. 
      Manetti, PhD; Department of Experimental and Clinical Medicine, Section of 
      Anatomy and Histology, University of Florence.
FAU - Guiducci, Serena
AU  - Guiducci S
AD  - From the Department of Experimental and Clinical Medicine, Section of Internal 
      Medicine; Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; 
      DENOthe Centre; Department of Experimental and Clinical Medicine, Section of 
      Anatomy and Histology, University of Florence, Florence, Italy.E. Romano, PhD; R. 
      Terenzi, MD; F. Peruzzi, MD; G. Fiori, MD; F. Nacci, MD; S. Bellando-Randone, MD, 
      PhD; M. Matucci-Cerinic, MD, PhD; S. Guiducci, MD, PhD, Department of 
      Experimental and Clinical Medicine, Section of Internal Medicine, Division of 
      Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; M. 
      Manetti, PhD; Department of Experimental and Clinical Medicine, Section of 
      Anatomy and Histology, University of Florence.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140901
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Antirheumatic Agents)
RN  - 0 (FAS protein, human)
RN  - 0 (Fas Ligand Protein)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (fas Receptor)
RN  - B72HH48FLU (Infliximab)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Antirheumatic Agents/*therapeutic use
MH  - Apoptosis/immunology
MH  - Arthritis, Rheumatoid/*blood/*drug therapy
MH  - Fas Ligand Protein/blood
MH  - Female
MH  - Humans
MH  - Infliximab/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
MH  - fas Receptor/*blood
OTO - NOTNLM
OT  - APOPTOSIS
OT  - DISEASE ACTIVITY
OT  - RHEUMATOID ARTHRITIS
OT  - SOLUBLE FAS
OT  - TNF-alpha INHIBITORS
EDAT- 2014/09/03 06:00
MHDA- 2016/05/18 06:00
CRDT- 2014/09/03 06:00
PHST- 2014/09/03 06:00 [entrez]
PHST- 2014/09/03 06:00 [pubmed]
PHST- 2016/05/18 06:00 [medline]
AID - jrheum.131544 [pii]
AID - 10.3899/jrheum.131544 [doi]
PST - ppublish
SO  - J Rheumatol. 2014 Oct;41(10):1961-5. doi: 10.3899/jrheum.131544. Epub 2014 Sep 1.